SG11202009971QA - Quinoline derivatives as inhibitors of axl/mer rtk and csf1r - Google Patents
Quinoline derivatives as inhibitors of axl/mer rtk and csf1rInfo
- Publication number
- SG11202009971QA SG11202009971QA SG11202009971QA SG11202009971QA SG11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA
- Authority
- SG
- Singapore
- Prior art keywords
- csf1r
- axl
- inhibitors
- quinoline derivatives
- rtk
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677902P | 2018-05-30 | 2018-05-30 | |
| PCT/EP2019/064214 WO2019229251A1 (fr) | 2018-05-30 | 2019-05-31 | Dérivés de quinoléine utilisés en tant qu'inhibiteurs d'axl/mer rtk et csf1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009971QA true SG11202009971QA (en) | 2020-11-27 |
Family
ID=66770463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009971QA SG11202009971QA (en) | 2018-05-30 | 2019-05-31 | Quinoline derivatives as inhibitors of axl/mer rtk and csf1r |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210163448A1 (fr) |
| EP (1) | EP3774776A1 (fr) |
| JP (2) | JP7390313B2 (fr) |
| KR (1) | KR20210020882A (fr) |
| CN (1) | CN112313216A (fr) |
| AU (1) | AU2019276359A1 (fr) |
| BR (1) | BR112020021370A2 (fr) |
| CA (1) | CA3097694A1 (fr) |
| IL (1) | IL278960B1 (fr) |
| MX (1) | MX2020011636A (fr) |
| PH (1) | PH12020551806A1 (fr) |
| SG (1) | SG11202009971QA (fr) |
| WO (1) | WO2019229251A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023186294A1 (fr) * | 2022-03-30 | 2023-10-05 | Qurient Co., Ltd. | Nouvelles formes de chlorhydrate de n-(5-((6,7-diméthoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl-4-(2,2,2-trifluoroéthoxy)-1h-pyrazole-3-carboxamide |
| CN117637185B (zh) * | 2024-01-25 | 2024-04-23 | 首都医科大学宣武医院 | 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7340096A (en) * | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| EP2311809A1 (fr) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (fr) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl |
| MX352844B (es) * | 2011-02-28 | 2017-12-11 | Calitor Sciences Llc | Compuestos de quinolina sustituidos y metodos de uso. |
| US10208034B2 (en) * | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
| AU2016249860B2 (en) * | 2015-04-14 | 2019-10-10 | Lead Discovery Center Gmbh | Quinoline derivatives as TAM RTK inhibitors |
-
2019
- 2019-05-31 BR BR112020021370-5A patent/BR112020021370A2/pt unknown
- 2019-05-31 SG SG11202009971QA patent/SG11202009971QA/en unknown
- 2019-05-31 KR KR1020207034321A patent/KR20210020882A/ko unknown
- 2019-05-31 US US17/047,961 patent/US20210163448A1/en active Pending
- 2019-05-31 AU AU2019276359A patent/AU2019276359A1/en active Pending
- 2019-05-31 WO PCT/EP2019/064214 patent/WO2019229251A1/fr active Application Filing
- 2019-05-31 CA CA3097694A patent/CA3097694A1/fr active Pending
- 2019-05-31 MX MX2020011636A patent/MX2020011636A/es unknown
- 2019-05-31 JP JP2020565928A patent/JP7390313B2/ja active Active
- 2019-05-31 CN CN201980036560.3A patent/CN112313216A/zh active Pending
- 2019-05-31 IL IL278960A patent/IL278960B1/en unknown
- 2019-05-31 EP EP19728645.3A patent/EP3774776A1/fr active Pending
-
2020
- 2020-10-29 PH PH12020551806A patent/PH12020551806A1/en unknown
-
2023
- 2023-10-06 JP JP2023174642A patent/JP2023168629A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL278960B1 (en) | 2024-04-01 |
| MX2020011636A (es) | 2020-12-07 |
| JP2021525270A (ja) | 2021-09-24 |
| JP2023168629A (ja) | 2023-11-24 |
| EP3774776A1 (fr) | 2021-02-17 |
| WO2019229251A1 (fr) | 2019-12-05 |
| CA3097694A1 (fr) | 2019-12-05 |
| BR112020021370A2 (pt) | 2021-01-19 |
| US20210163448A1 (en) | 2021-06-03 |
| CN112313216A (zh) | 2021-02-02 |
| IL278960A (en) | 2021-01-31 |
| AU2019276359A1 (en) | 2020-10-29 |
| PH12020551806A1 (en) | 2021-05-17 |
| KR20210020882A (ko) | 2021-02-24 |
| JP7390313B2 (ja) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202113146UA (en) | Covalent inhibitors of kras | |
| HK1259232A1 (zh) | Menin-mll的取代抑制劑及其使用方法 | |
| IL267090A (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them | |
| EP3684361A4 (fr) | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation | |
| EP3700527A4 (fr) | Inhibiteurs de papd5 et leurs méthodes d'utilisation | |
| HK1249513A1 (zh) | Kras的稠合三環抑制劑及其使用方法 | |
| EP3600318A4 (fr) | Procédés d'utilisation d'inhibiteurs d'ehmt2 | |
| IL290727A (en) | A formulation for inhibiting the formation of 5-ht 2b agonists and methods of using the same | |
| IL267455A (en) | Phosphodiesterase inhibitors and methods of treating bacteria | |
| IL247970A (en) | Quinoline history as smo inhibitors | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3565520A4 (fr) | Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation | |
| EP3558998A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs méthodes d'utilisation | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| EP3638229A4 (fr) | Inhibiteurs de la kinase alk2 contenant de l'imidazole | |
| EP3609882A4 (fr) | Inhibiteurs hétérocycliques de pcsk9 | |
| EP3710430A4 (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| EP3183256A4 (fr) | Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation | |
| IL278960A (en) | History of quinoline as inhibitors of AXL/MER RTK and CSF1R | |
| PL3558321T3 (pl) | Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b | |
| IL270703B1 (en) | History of Reziquimod | |
| IL281216A (en) | Inhibitors of glutaminyl cyclase | |
| ZA202100140B (en) | Pyridopyrimidinone derivatives for use as axl inhibitors | |
| EP3237619B8 (fr) | Compositions et procédés pour inhiber l'expression de adamts-5 et adam17 | |
| AU2017900935A0 (en) | Heterocyclic inhibitors of PCSK9 |